Starting point
Semaglutide (Wegovy, Ozempic) was the drug that proved pharmaceutical weight loss could be clinically meaningful. Everything since is building on that foundation. But 'after semaglutide' has already partly happened — tirzepatide is already approved and substantially more effective.
Semaglutide represented a genuine inflection point in obesity medicine. When the STEP 1 trial published in 2021, 15% average body weight loss was a number the obesity medicine community hadn't seen from any medication. It changed the standard of care and triggered an acceleration of research into related mechanisms.
Three years later, the landscape has already shifted. Tirzepatide (Zepbound) is approved and achieves 20-22% average weight loss. And five more drugs are in Phase 3 trials, each building on semaglutide's foundation in different ways.
What Semaglutide Actually Did
Semaglutide's mechanism — GLP-1 receptor agonism — wasn't new. GLP-1 drugs existed before semaglutide (liraglutide, exenatide). What made semaglutide different was pharmacokinetics: its extended half-life of 165-184 hours meant once-weekly dosing, and at high doses (2.4mg), it produced sustained, clinically meaningful weight loss. The side effect profile was real but manageable. The results were consistent across demographics.
The drugs coming after it don't abandon GLP-1 agonism — they build on it by adding complementary mechanisms.
The Three Directions "After Semaglutide"
1. More receptors: Tirzepatide added GIP. Retatrutide adds GIP plus glucagon. More receptor targets appear to produce more weight loss, up to the ceiling current data shows.
2. Different second pathways: CagriSema keeps semaglutide's GLP-1 agonism but adds amylin (cagrilintide). MariTide activates GLP-1 but blocks GIP — the opposite of tirzepatide. Different secondary mechanisms may be better for different patient populations.
3. Oral formulation: Orforglipron and amycretin attempt to bring GLP-1 efficacy to a pill format without Rybelsus's limitations.
| Drug | What it adds to GLP-1 | Key advantage |
|---|---|---|
| Tirzepatide (approved) | GIP agonism | Best approved efficacy (~22%) |
| Retatrutide | GIP + Glucagon agonism | Highest trial weight loss (~24%) |
| CagriSema | Amylin agonism | Distinct pathway, Phase 3 data |
| Orforglipron | Oral small molecule | No injection required |
| MariTide | GIP antagonism (monthly) | Monthly injection only |
Find a GLP-1 option matched to your state and budget in 60 seconds.
Get My Match →The Question Patients Are Actually Asking
When people ask "what comes after semaglutide," they usually mean: "Is there something better I should wait for?" The honest answer: tirzepatide is already better and already available. The pipeline offers meaningful additional advancement, but the gap between 20% (tirzepatide) and 24% (retatrutide) is smaller than the gap between waiting and not.
The more clinically precise "after semaglutide" question is: which of these drugs will be better for a specific patient who isn't responding adequately to semaglutide? That question won't be answerable until head-to-head data exists, which requires Phase 4 studies or comparative effectiveness research after multiple drugs are approved.
See the full future GLP-1 medications hub, or compare retatrutide vs semaglutide directly.
Frequently Asked Questions
Is tirzepatide the next thing after semaglutide?
Yes — it's already here and already approved. Tirzepatide (Zepbound) is FDA-approved for obesity and produces 20-22% average weight loss, substantially more than semaglutide's 15%.
Should I switch from Wegovy to Zepbound?
That's a clinical decision for you and your provider. If you're achieving good results on Wegovy, there may not be a reason to switch. If results are inadequate, tirzepatide is worth discussing.
What is the next GLP-1 to be approved?
CagriSema and orforglipron are furthest along in Phase 3, with potential approval as early as 2026-2027.
Ready to find your match?
Answer 5 quick questions and see licensed GLP-1 programs available in your state — matched to your budget. Free. No obligation.
Get My Match — Free →